Volition announces the launch of the nu.q® vet cancer screening test in the u.s. and europe through heska's reference laboratories

Henderson, nev. , nov. 3, 2022 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, announces the launch of its nu.q® vet cancer screening test across the u.s. and the forthcoming launch in europe by heska corporation (nasdaq: hska) ("heska"), a leading global provider of advanced veterinary diagnostics, through heska's veterinary diagnostic laboratories.
VNRX Ratings Summary
VNRX Quant Ranking